Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 55.805 USD 1.37% Market Closed
Market Cap: $113.6B

Relative Value

The Relative Value of one BMY stock under the Base Case scenario is 65.877 USD. Compared to the current market price of 55.805 USD, Bristol-Myers Squibb Co is Undervalued by 15%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BMY Relative Value
Base Case
65.877 USD
Undervaluation 15%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

BMY Competitors Multiples
Bristol-Myers Squibb Co Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Bristol-Myers Squibb Co
NYSE:BMY
113.4B USD 2.4 18.8 6.7 8.8
US
Eli Lilly and Co
NYSE:LLY
985.1B USD 16.6 53.5 35.9 38.5
US
Johnson & Johnson
NYSE:JNJ
554.2B USD 5.9 20.7 14.4 17.7
CH
Roche Holding AG
SIX:ROG
283.2B CHF 4.6 30.1 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
214.8B GBP 5.1 31.6 15.1 22.1
CH
Novartis AG
SIX:NOVN
224.7B CHF 5.2 20.1 12.6 16.3
US
Merck & Co Inc
NYSE:MRK
281.3B USD 4.4 14.8 10.4 12.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.3 16 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
150.9B USD 2.4 15.4 7.7 10.6
FR
Sanofi SA
PAR:SAN
97.3B EUR 1.7 8.2 7.6 7.6
P/E Multiple
Earnings Growth PEG
US
Bristol-Myers Squibb Co
NYSE:BMY
Average P/E: 22.9
18.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.7
6%
3.4
CH
Roche Holding AG
SIX:ROG
30.1
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
38%
0.8
CH
Novartis AG
SIX:NOVN
20.1
17%
1.2
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.4
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Bristol-Myers Squibb Co
NYSE:BMY
Average EV/EBITDA: 42.5
6.7
-9%
N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.4
2%
7.2
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
CH
Novartis AG
SIX:NOVN
12.6
6%
2.1
US
Merck & Co Inc
NYSE:MRK
10.4
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
7.6
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Bristol-Myers Squibb Co
NYSE:BMY
Average EV/EBIT: 90.6
8.8
10%
0.9
US
Eli Lilly and Co
NYSE:LLY
38.5
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.7
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.1
23%
1
CH
Novartis AG
SIX:NOVN
16.3
12%
1.4
US
Merck & Co Inc
NYSE:MRK
12.4
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
7.6
6%
1.3